| Patient | Pierre Le Moyne d'Iberville |
|---|---|
| Date of birth | 1982-07-16 |
| Identifiers | MRN HR-ET014-SYN; SSN (made up) 000-14-7260 |
| Document date | 2026-04-21 |
| Author | Marguerite Delacroix-Boateng, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Periodic adult preventive visit. [S]
Mr. Le Moyne d'Iberville is a 43-year-old naval commander treated seven weeks ago with chloroquine and primaquine for relapsing P. vivax malaria, who comes for a preventive visit. He has had no fever, chills or sweats since the treatment and no dark urine. He carries his fever card. He is preparing a squadron that is expected to sail early next year for French Guiana and the French Antilles, and his pre-travel vaccines are planned for the summer visit. He walks the dockyard most days and sleeps about seven hours. He wants his prevention brought up to date before the deployment. [S]
| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 43 |
| Malaria | No fever since chloroquine and primaquine |
| Deployment | Expected to sail early next year |
| Mood | PHQ-2 0 |
| Alcohol | AUDIT-C 3 |
Health risk assessment. Completed by the patient on paper in the waiting room and reviewed with him face to face by Dr. Delacroix-Boateng. [S]
| Domain | Finding |
|---|---|
| Self-rated health | Good since the malaria treatment |
| Psychosocial | Busy and under pressure preparing the squadron; supportive household |
| Tobacco | Never |
| Alcohol | Wine with dinner, about eight drinks a week; AUDIT-C 3 |
| Physical activity | Walks the dockyard most days; sails |
| Nutrition | Regular meals; fish and bread, few vegetables |
| Sleep | About seven hours |
| Sexual health | No concerns; one partner |
| Safety | Works on ladders and rigging in the dockyard; can swim |
| Road safety | Wears a seat belt |
| Activities of daily living | Independent |
| Hearing and vision | Hearing normal by his report; reads without glasses |
| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | No fever, chills, night sweats, or weight loss |
| Eyes | Negative | No change in vision |
| Ears, nose, mouth, and throat | Negative | No hearing change or dental pain |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | No abdominal pain, jaundice, or change in bowel habit |
| Genitourinary | Negative | No dark urine or urinary symptoms |
| Musculoskeletal | Negative | No joint pain |
| Integumentary | Negative | No rashes or changing moles |
| Neurological | Negative | No headache or numbness |
| Psychiatric | Negative | Mood good; PHQ-2 score 0 |
11 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Chloroquine phosphate 500 mg tablet: 1,000 mg (two tablets) at once, then 500 mg at 6, 24 and 48 hours; take with food | 1,000 mg, then 500 mg at 6, 24 and 48 hours (2,500 mg salt in total) | Oral route | 2026-03-03 to 2026-03-05 | completed | S |
| Primaquine phosphate 26.3 mg tablet (15 mg base): two tablets (30 mg base) by mouth daily with food for 14 days | 30 mg base once daily for 14 days | Oral route | 2026-03-03 to 2026-03-16 | completed | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-04-21 | Body height | 175 | cm | S |
| 2026-04-21 | Body weight | 69.2 | kg | S |
| 2026-04-21 | Body mass index (BMI) [Ratio] | 22.6 | kg/m2 | S |
| 2026-04-21 | Systolic blood pressure | 120 | mm[Hg] | S |
| 2026-04-21 | Diastolic blood pressure | 76 | mm[Hg] | S |
| 2026-04-21 | Heart rate | 64 | /min | S |
| 2026-04-21 | Respiratory rate | 14 | /min | S |
| 2026-04-21 | Body temperature | 36.6 | Cel | S |
| 2026-04-21 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-04-21 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-04-21 | Total score [AUDIT-C] | 3 | {score} | S | ||
| 2026-04-21 | Cholesterol [Mass/volume] in Serum or Plasma | 192 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-04-21 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 52 | mg/dL | >=40 mg/dL | Normal | S |
| 2026-04-21 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 116 | mg/dL | Below 130 | Normal | S |
| 2026-04-21 | Triglyceride [Mass/volume] in Serum or Plasma | 120 | mg/dL | <=149 mg/dL | Normal | S |
Vital signs recorded on 2026-04-21; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| Constitutional | Weathered, fit-looking man; weight 69.2 kg, BMI 22.6; blood pressure 120/76, pulse 64, temperature 36.6 C |
| Eyes | Sclerae white; no pallor |
| Neck | No lymph node or thyroid enlargement |
| Cardiovascular | Regular rhythm; normal heart sounds; no murmur |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft and non-tender; spleen not palpable |
| Skin | Sun-weathered face and hands; no suspicious lesions |
| Psychiatric | Alert and engaged |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Recurrent episodes of fever with shaking chills and drenching sweats, three in the past two years, each beginning months after naval service in malaria-endemic areas; the first diagnosed as malaria abroad on a blood smear with the species not recorded and treated with chloroquine alone, the later two treated with chloroquine without testing; the last ended six weeks before intake; afebrile and well at intake; cause not established at intake; infectious diseases consultation requested | resolved | confirmed | R50.9 | S — Synthetic presenting problem anchored to his documented recurrent attacks of illness called malaria; superseded by the diagnosis at the infectious diseases consultation. |
| Relapsing Plasmodium vivax malaria: P. vivax DNA detected by PCR in blood drawn between attacks, with negative smears and rapid antigen test; after three relapses treated without antirelapse therapy; normal quantitative G6PD | resolved | confirmed | B51.9 | S — Synthetic modern diagnosis made at the infectious diseases consultation, linked to his documented recurrent attacks of illness called malaria; the species and the PCR result are synthetic. |
| Pre-travel care for a naval deployment, expected to sail early next year, to French Guiana and the French Antilles: yellow fever vaccination required for entry to French Guiana, malaria prevention, dengue, chikungunya and typhus prevention by vector avoidance, food and water safety, and travel vaccines | active | confirmed | Z71.84 | S — Synthetic modern counterpart of his documented preparation of a tropical campaign in 1705. |
Personalized prevention plan. A written copy was given to the patient. [S]
| Service | Status | Detail |
|---|---|---|
| Blood pressure | Completed today | 120/76 mmHg |
| Depression screening | Completed today | PHQ-2 score 0 |
| Tobacco use | Completed today | Never used tobacco |
| Unhealthy alcohol use | Completed today | AUDIT-C 3; brief advice given |
| Cholesterol and cardiovascular risk | Completed today | LDL cholesterol 116 mg/dL, HDL 52 mg/dL; no diabetes, smoking or hypertension; no statin indicated |
| Diabetes screening | Not indicated | BMI 22.6 with no other risk factor; glucose 92 mg/dL at intake |
| Colorectal cancer screening | Not indicated | Begins at 45; no family history recorded |
| HIV screening | Ordered | One-time screening for adults 15 to 65; drawn today with his agreement |
| Hepatitis C screening | Ordered | One-time antibody test for adults 18 to 79; drawn today |
| Hepatitis B screening and vaccination | Ordered | One-time triple panel drawn today; hepatitis B vaccine before the deployment if he is not immune |
| Tetanus, diphtheria, and pertussis | Completed today | Tdap today; no dose recorded in the last ten years |
| Travel vaccines | Due | Yellow fever, hepatitis A and typhoid at the pre-travel visit, as the consultant advised |
| Influenza vaccine | Due | In the autumn, before the deployment |
| Skin cancer counseling | Completed today | Sun protection at sea discussed; hat and sunscreen |
Immunizations given today: Tdap vaccine [S]
Guideline basis: Treatment of Uncomplicated Malaria (clinical guidance) (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)
Follow-up: Pre-travel vaccine visit in the summer. Screening results through the patient portal. Next scheduled visit 2026-07-28: pre-travel visit: yellow fever, hepatitis A, hepatitis B and typhoid vaccines, and the travel plan. [S]
Voluntary advance care planning discussion of about 20 minutes, with his consent, before a long deployment at sea far from hospital care. He named a health care agent and a second agent, and a health care proxy form was completed; both are recorded in the chart and are not named here. He wants full treatment if he is ill or injured, including evacuation to the nearest hospital. He asked for a short medical summary, including his malaria history and G6PD result, to carry with the ship's medical officer. The plan will be revisited before he sails. [S]